9 Results for "

VCaP cell

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "VCaP cell" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-149862
CAS No.: 2632305-17-8
Purity:  98.19%
Research Areas:  

Cancer

ARD-2051 is a selective and orally active androgen receptor (AR) PROTAC degrader. ARD-2051 achieves DC50 values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 exhibits effective anti-tumor activity in VCaP xenograft mice model. ARD-2051 can be used for the research of prostate cancer .
loading...
    loading...
Cat. No.: HY-158113
CAS No.: 3037549-86-0
Research Areas:  

Cancer

CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .
loading...
    loading...
Cat. No.: HY-133045
CAS No.: 2701565-76-4
Purity:  98.04%
Target:  

Ligands for E3 Ligase

Research Areas:  

Cancer

VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC50 values of 0.2-1 nM .
loading...
    loading...
Cat. No.: HY-133020
CAS No.: 2666951-70-6
Purity:  99.94%
Research Areas:  

Cancer

ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC50 values of 0.2-1 nM . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-139893
CAS No.: 2756327-67-8
Purity:  ≥95.0%
Target:  

RIO Kinase

Research Areas:  

Cancer

ERGi-USU-6 mesylate (Compound 7b) is an inhibitor of ERG and RIOK2 (IC50 values: 0.17 and 0.13 μM in VCaP cells, respectively). ERGi-USU-6 mesylate exhibits anticancer activity against ERG-positive prostate cancer .
loading...
    loading...
Cat. No.: HY-156751
CAS No.: 2753650-84-7
Synonyms: (Rac)-RO7656594; PROTAC AR Degrader-6
Research Areas:  

Cancer

(Rac)-GDC-2992 ((Rac)-RO7656594; PROTAC AR Degrader-6) (Compound 1) is an androgen receptor (AR) PROTAC degrader with a DC50 of 10 nM in VCaP cells. (Rac)-GDC-2992 blocks androgen receptor-mediated signaling processes and also degrades the receptor itself. (Rac)-GDC-2992 can be used in prostate cancer research, including studies on castration-resistant prostate cancer and metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-133044
CAS No.: 2581824-70-4
Target:  

PROTAC Linkers

Research Areas:  

Cancer

Boc-Pip-alkyne-Ph-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-Pip-alkyne-Ph-COOH can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 effectively induces degradation of androgen receptor (AR) protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC50 values of 0.2-1 nM . Boc-Pip-alkyne-Ph-COOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-169278
CAS No.: 2760247-27-4
Target:  

PROTACs SWI/SNF Complex

Research Areas:  

Cancer

PROTAC SMARCA2 degrader-26 (compound 45) is a potent SMARCA2 PROTAC degrader. PROTAC SMARCA2 degrader-26 induces SMARCA2 and SMARCA4 degradation in VCaP cells with the percent degradation of 94% and 57% for SMARCA2 and SMARCA4, respectively. PROTAC SMARCA2 degrader-26 shows antiproliferative activity .
loading...
    loading...
Cat. No.: HY-173640
CAS No.: 2785317-21-5
Research Areas:  

Cancer

ID11916 is an orally active androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. ID11916 blocks androgen binding to AR, nuclear translocation, and androgen-dependent transcriptional activity of AR, while increasing intracellular cGMP levels and activating PKG via inhibition. ID11916 shows potent anti-cancer effect in prostate cancer cell lines VCaP and 22Rv1 and in AR-positive breast cancer cell lines SK-BR-3 .
loading...
    loading...